Ajanta Pharma FY26 Annual Report: Revenue Rs 5,453 cr, PAT Rs 1,056 cr

Exceptional ItemResults View source PDF Explain this filing

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹3060.00

prior close

₹3067.60

announcement price

In-mkt

timing

Nifty Midcap 150market+0.5%+0.3% vs market

Pharmaceuticals peers, median of 160sector+0.7%+0.1% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.1

15m

+0.3

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+0.5+0.3+0.7+0.1

Next day

+0.4+0.8-0.5+1.1-0.7

+4.2+1.3+3.0+1.4+2.9

+4.2+0.3+3.9+2.1+2.1

+6.4+0.4+6.0+2.6+3.8

+4.3-0.2+4.4+1.8+2.4

+11.9-0.1+11.9+3.4+8.4

15d

+10.0+1.7+8.3+4.0+6.0

+13.3+1.3+12.0+4.5+8.8

+21.2+2.5+18.7+3.2+18.0

+16.6+0.5+16.1+8.9+7.7

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajanta Pharma's FY26 Annual Report shows revenue up 17% to Rs 5,453 cr, adjusted EBITDA up 18% to Rs 1,498 cr (27% margin), and PAT up 15% to Rs 1,056 cr. US Generics surged 49% to Rs 1,557 cr. India grew 14%, Africa 15%, Asia declined 1% on Middle East issues. EPS rose to Rs 85. Dividend payout Rs 350 cr. 47th AGM on July 16, 2026.

Likely market impact

Strong FY26 with revenue crossing Rs 5,000 cr and PAT Rs 1,000 cr. US Generics surged 49%. Rs 350 cr dividend. AGM on July 16.